Use of danaparoid during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia.
Olin
D A
DA
Department of Anesthesiology, University of Florida College of Medicine, and the Gainesville Veterans Affairs Medical Center, USA.
Urdaneta
F
F
Lobato
E B
EB
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use*; D002315:Cardiopulmonary Bypass; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000601:surgery; D003871:Dermatan Sulfate / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D016041:Heart-Lung Transplantation; D006493:Heparin / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013921:Thrombocytopenia / Q000139:chemically induced*
D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006493:Heparin; D006497:Heparan Sulfate; C035838:danaparoid